Merck KGaA agrees to buy Bio-Techne for USD 73 a share in USD 11.3 billion deal

Bio-Techne Corporation

Bio-Techne Corporation

TECH

0.00
  • Merck KGaA agreed to buy Bio-Techne for USD 73 per share in cash, valuing the deal at about USD 11.3 billion.
  • Offer implies a 36% premium to the one-month volume-weighted average share price.
  • Closing targeted for late 2026 or early 2027, subject to shareholder and regulatory clearances.
  • Merck expects about EUR 140 million of annual cost synergies, fully realized by year 3 post-close.
  • Merck plans to fund the purchase with cash on hand and new debt, aiming to keep an investment-grade credit rating.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606250610PR_NEWS_USPR_____CG92233) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.